# US 11,998,653 B2 · Method for treating active bleeding by sequentially applying a biocompatible hemostatic composition and a sealant composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,998,653 B2
- Document ID: US11998653B2
- Status: Granted
- Kind: B2
- Application number: 16/959,994
- Filed: 2019-01-10
- Published: 2021-03-04
- Granted: 2024-06-04
- Earliest claimed: 2018-01-12
- Applicants: Beijing Universal Likang Technology Co., LTD.
- Inventors: Xin Ji; Xueshen Shi; Xiaoguang Zhang
- Web page: https://patentgrep.com/patent/US11998653B2

## CPC

- A61L 24/0031: {Hydrogels or hydrocolloids}
- A61L 24/046: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence)}
- A61L 24/08: Polysaccharides {(A61L24/043 takes precedence)}
- A61L 24/106: {Fibrin; Fibrinogen}
- A61L 26/0023: {Polysaccharides}
- C08L 3/02: Starch; Degradation products thereof, e.g. dextrin
- C08L 5/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- C08L 71/02: Polyalkylene oxides
- A61L 2400/04: Materials for stopping bleeding
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

The present specification describes a biocompatible hemostatic composition and a biocompatible tissue sealant, which when used in combination provides a safe and effective method of achieving hemostasis. The biocompatible composition and sealant may be applied either on a surface of the patient's body, or inside the body cavity. The combination may be used to control bleeding from external wounds and internal injuries, as well as to minimize bleeding during surgical procedures.

## Claims

### Claim 1

A method of using a biocompatible carboxymethyl starch in combination with a biocompatible polyethylene glycol (PEG) blend to treat a bleeding wound within or on a mammal, comprising:
applying a first amount of said biocompatible carboxymethyl starch to said bleeding wound; and,
applying a second amount of said biocompatible polyethylene glycol (PEG) blend to the bleeding wound, wherein the biocompatible polyethylene glycol (PEG) blend comprises at least one of PEG succinimidyl glutarate blended with PEG thiol, PEG succinimidyl glutarate blended with PEG amine, PEG maleimide blended with PEG thiol, or PEG maleimide blended with PEG amine, wherein the first amount plus the second amount equals a total amount, wherein the first amount is approximately 75% of the total amount, wherein the second amount is approximately 25% of the total amount and wherein said first amount and said second amount in combination are sufficient to cause at least one of: hemostasis in said bleeding wound, wound sealing in said wound, reducing exudation of said bleeding wound, promoting tissue healing of said wound, protecting a surface of said wound, and avoiding infection of said wound.

### Claim 2 (depends on 1)

The method of claim 1, wherein said biocompatible carboxymethyl starch is at least one of a sodium carboxymethyl starch or a crosslinked carboxymethyl starch.

### Claim 3 (depends on 1)

The method of claim 1, wherein said biocompatible carboxymethyl starch is a powder and wherein particle sizes of said biocompatible carboxymethyl starch powder range from 1-1000 micrometers.

### Claim 4 (depends on 3)

The method of claim 3, wherein particles of said biocompatible carboxymethyl starch powder have a water absorbency capacity greater than or equal to 12 ml/g.

### Claim 5 (depends on 3)

The method of claim 3, wherein particles of said biocompatible carboxymethyl starch powder have a molecular weight of 15,000 Daltons to 250,000 Daltons.

### Claim 6 (depends on 1)

The method of claim 1, wherein said biocompatible PEG blend is a powder.

### Claim 7 (depends on 1)

The method of claim 1, wherein the bleeding wound is located in tissue of at least one of the mammal's respiratory tract, digestive tract, genital tract, and gastrointestinal tract.

### Claim 8 (depends on 1)

The method of claim 1, wherein applying said first amount and said second amount are repeated until complete hemostasis is achieved.

### Claim 9 (depends on 1)

The method of claim 1, wherein the biocompatible carboxymethyl starch and biocompatible polyethylene glycol (PEG) blend are sequentially applied.

### Claim 10 (depends on 1)

The method of claim 1, wherein the biocompatible carboxymethyl starch is applied to the said wound first and, after said application, the biocompatible polyethylene glycol (PEG) blend is then applied.

### Claim 11 (depends on 1)

The method of claim 1, wherein approximately 50% of the biocompatible PEG blend is PEG succinimidyl glutarate and approximately 50% of the biocompatible PEG blend is PEG thiol.

### Claim 12 (depends on 1)

The method of claim 1, wherein approximately 50% of the biocompatible PEG blend is PEG succinimidyl glutarate and approximately 50% of the biocompatible PEG blend is PEG amine.

### Claim 13 (depends on 1)

The method of claim 1, wherein approximately 50% of the biocompatible PEG blend is PEG maleimide and approximately 50% of the biocompatible PEG blend is PEG thiol.

### Claim 14 (depends on 1)

The method of claim 1, wherein approximately 50% of the biocompatible PEG blend is PEG maleimide and approximately 50% of the biocompatible PEG blend is PEG amine.